Geron Corporation (NASDAQ:GERN) Given Consensus Rating of “Hold” by Analysts

Geron Corporation (NASDAQ:GERN) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.1667.

A number of research analysts recently commented on GERN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. TD Cowen restated a “buy” rating on shares of Geron in a research note on Thursday, January 29th.

Institutional Trading of Geron

Institutional investors and hedge funds have recently bought and sold shares of the company. 55 North Private Wealth LLC acquired a new stake in Geron during the fourth quarter valued at approximately $29,000. LCM Capital Management Inc raised its stake in Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC acquired a new stake in Geron during the fourth quarter valued at approximately $33,000. Caitong International Asset Management Co. Ltd raised its stake in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 24,410 shares in the last quarter. Finally, Swiss Life Asset Management Ltd raised its stake in Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 11,182 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Trading Up 3.3%

Shares of GERN opened at $1.55 on Thursday. The company has a market capitalization of $993.40 million, a P/E ratio of -11.92 and a beta of 0.67. Geron has a one year low of $1.04 and a one year high of $2.01. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66. The stock has a 50-day moving average price of $1.64 and a 200 day moving average price of $1.42.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.02). The business had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $50.43 million. Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%. Sell-side analysts forecast that Geron will post -0.05 EPS for the current fiscal year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.